Last reviewed · How we verify
Corticosteroids, IV
Corticosteroids suppress immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
Corticosteroids suppress immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Acute inflammatory and autoimmune disorders, Severe allergic reactions, Cerebral edema.
At a glance
| Generic name | Corticosteroids, IV |
|---|---|
| Also known as | Solu-Medrol |
| Sponsor | Hoffmann-La Roche |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology, Rheumatology, Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Intravenous corticosteroids rapidly enter systemic circulation to exert broad immunosuppressive and anti-inflammatory effects. They inhibit phospholipase A2, reduce cytokine and chemokine synthesis, suppress T-cell proliferation, and stabilize lysosomal membranes. This makes them effective for acute inflammatory and autoimmune conditions requiring rapid systemic intervention.
Approved indications
- Acute inflammatory and autoimmune disorders
- Severe allergic reactions
- Cerebral edema
- Acute exacerbations of chronic inflammatory conditions
- Immunosuppression in transplantation
Common side effects
- Hyperglycemia
- Hypertension
- Insomnia
- Mood changes (agitation, depression)
- Immunosuppression / increased infection risk
- Hypokalemia
- Fluid retention
Key clinical trials
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) (PHASE1, PHASE2)
- Gene Replacement Therapy for Treatment of Paediatric Patients With CTNNB1 Neurodevelopmental Syndrome (PHASE1, PHASE2)
- Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids (PHASE1, PHASE2)
- A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma (PHASE3)
- A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01) (PHASE2)
- MAGIC Ruxolitinib for aGVHD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Corticosteroids, IV CI brief — competitive landscape report
- Corticosteroids, IV updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI